RA Capital Discloses Significant Stake in Corbus Pharma (CRBP)

TL;DR

**RA Capital just bought a big chunk of Corbus Pharma, signaling institutional confidence.**

AI Summary

RA Capital Management, L.P., a prominent investment firm, filed an SC 13G on February 12, 2024, disclosing its ownership in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP). This filing indicates that RA Capital Management, L.P. now holds a significant stake in Corbus, with the event triggering the filing occurring on February 2, 2024. This matters to investors because a major institutional investor like RA Capital taking a position can signal confidence in Corbus's future prospects, potentially influencing other investors and the stock price.

Why It Matters

This filing reveals a major institutional investor's belief in Corbus Pharmaceuticals, which could be a positive signal for the company's future and its stock performance.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of an institutional investment and does not inherently present a direct risk to investors.

Analyst Insight

A smart investor would research Corbus Pharmaceuticals' recent developments and financial health to understand why RA Capital Management, L.P. took a significant stake, potentially indicating a positive outlook for the company.

Key Numbers

• $0.0001 — Par Value per Share (The par value of Corbus Pharmaceuticals Holdings, Inc. Common Stock.)

Key Players & Entities

• RA Capital Management, L.P. (company) — the reporting person and institutional investor
• Corbus Pharmaceuticals Holdings, Inc. (company) — the issuer of the securities
• PETER KOLCHINSKY (person) — group member associated with RA Capital
• RA CAPITAL HEALTHCARE FUND, L.P. (company) — group member associated with RA Capital
• RAJEEV SHAH (person) — group member associated with RA Capital
• February 2, 2024 (date) — date of event requiring the filing
• February 12, 2024 (date) — date the SC 13G was filed
• $0.0001 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

• Other institutional investors may increase their positions in Corbus Pharmaceuticals, following RA Capital's lead. (Corbus Pharmaceuticals Holdings, Inc.) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• tm245429d27_sc13g.htm (SC 13G) — 76KB
• tm245429d27_ex1.htm (EX-99.1) — 8KB
• 0001104659-24-014646.txt ( ) — 85KB

(a). Name of Issuer

Item 1(a). Name of Issuer: Corbus Pharmaceuticals Holdings, Inc. (the “Issuer”)

(b). Address of Issuer’s Principal Executive Offices

Item 1(b). Address of Issuer’s Principal Executive Offices: 500 River Ridge Drive, Norwood, Massachusetts 02062

(a). Names of Persons Filing

Item 2(a). Names of Persons Filing: The names of the persons filing this report (collectively, the “Reporting Persons”) are: RA Capital Management, L.P. (“RA Capital”) Peter Kolchinsky Rajeev Shah RA Capital Healthcare Fund, L.P. (the “Fund”)

(b). Address of Principal Business Office or, if None, Residence

Item 2(b). Address of Principal Business Office or, if None, Residence: The address of the principal business office of each of the Reporting Persons is: c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

(c). Citizenship

Item 2(c). Citizenship: RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United

(d). Title of Class of Securities

Item 2(d). Title of Class of Securities: Common Stock, par value $0.0001 per share (“Common Stock”)

(e). CUSIP Number

Item 2(e). CUSIP Number: 21833P301

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.

Ownership

Item 4. Ownership. The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The beneficial ownership percentages reported are based on 10,336,821 shares of Common Stock outstanding as of February 2, 2024, as disclosed in the Issuer’s Prospectus Supplement dated January 31, 2024, filed with the Securities and Exchange Commission on February 1, 2024. On February 2, 2024, the Fund acquired 500,000 shares of Common Stock, resulting in the beneficial ownership of the Reporting Persons exceeding 5% of the Issuer’s outstanding Common Stock. As of the date of the filing of this report, the Reporting Persons beneficially own 430,182 shares of Common Stock, representing less than 5% of the Issuer’s outstanding Common Stock. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsk

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group. Not applicable.

Certification

Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit List Exhibit 1: Joint Filing Agreement SIGNATURE After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: February 12, 2024 RA CAPITAL MANAGEMENT, L.P. By: /s/ Peter Kolchinsky Name: Peter Kolchinsky Title: Authorized Signatory PETER KOLCHINSKY /s/ Peter Kolchinsky RAJEEV SHAH /s/ Rajeev Shah RA CAPITAL HEALTHCARE FUND, L.P. By: RA Capital Healthcare Fund GP, LLC Its: General Partner By: /s/ Peter Kolchinsky Name: Peter Kolchinsky Title: Manager

View Full Filing

View this SC 13G filing on SEC EDGAR